Clinical trials: Tongue Squamous Cell Carcinoma
Soft Tissue Tumors of the Tongue, Squamous Cell Carcinoma
Study of the Relationship Between Clinical, Imaging and Biological Data in Patients With Squamous Cell Carcinoma of the Tongue
Squamous cell carcinoma (SCC) could be a very aggressive cancer and has a bad prognosis if not detected early and thus is associated with high mortality.
- Conditions
- Soft Tissue Tumors of the Tongue, Squamous Cell Carcinoma, Proton Magnetic Resonance Spectroscopy, Transcriptomics
- Trial name
- ClimaBio (NCT06450080)
- Testing
- MRI and MRS acquisitions
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00507767
- Testing
- dasatinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer
RATIONALE: Imaging procedures, such as PET/CT scan, produce pictures of areas inside the body and may help doctors detect residual disease and plan the best treatment.
- Trial name
- NCT00720070
- Testing
- positron emission tomography/computed tomography, therapeutic conventional surgery
- Where
- United Kingdom
- Volunteers
- 560 people
- Sponsor
- Warwick Medical School
Head and Neck Cancer
Vaccine Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00404339
- Testing
- mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Robert Ferris
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This pilot randomized phase I/II trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with cetuximab and to see how well it works in treating patients with recurrent or metastatic head and…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01816984
- Testing
- PI3K inhibitor BKM120, cetuximab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
- Trial name
- IRESSA&H&N (NCT00681967)
- Testing
- Gefitinib
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01142414
- Testing
- panitumumab, cisplatin, fluorouracil
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer
Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- CAPRA (NCT01333085)
- Testing
- carboplatin, RAD001, paclitaxel
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Head and Neck Cancer
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00851877
- Testing
- Cetuximab, Cisplatin, Nab-Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Cancer, Head and Neck Neoplasms
Arabic PRO Measures for Head and Neck Cancer Radiotherapy.
The goal of Arabic patient-reported outcome measures during radiotherapy for head and neck cancer is to test the patient-reported outcome measure (PROM) tools.
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer
- Trial name
- PROMs (NCT06662929)
- Testing
- Radiation
- Where
- Saudi Arabia
- Volunteers
- 125 people
- Sponsor
- King Saud University
Tongue Neoplasms, Carcinoma
Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line
In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than…
- Trial name
- NCT03288298
- Testing
- luteolin, nano-luteolin
- Volunteers
- 4 people
- Sponsor
- Cairo University
Oral Squamous, Cell Carcinoma
Radio/Pathological Evaluation of Tongue Cancer Infiltration
The aim of the study is to assess the good correlation and prediction of the DOI for the post-operative pathological results and prognosis.
- Trial name
- RaP E ToC (NCT04821128)
- Testing
- Radiologic and pathological review.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Head and Neck Cancer
Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899704
- Testing
- microarray analysis, allele-specific oligonucleotide real-time quantitative polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Oral Squamous Cell Carcinoma, Carcinoma of Buccal Mucosa
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
This is a phase II randomized clinical trial to study the effect of COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis.
- Conditions
- Oral Squamous Cell Carcinoma, Carcinoma of Buccal Mucosa, Tongue Cancers, Head and Neck Cancers
- Trial name
- ERLO-XIB (NCT02748707)
- Testing
- Arm1, Arm 2, Arm 3
- Where
- India
- Volunteers
- 64 people
- Sponsor
- Tata Memorial Hospital
Oral Leukoplakia, Oral Leukoplakia of Tongue
Prediction of Malignant Transformation of Oral Leukoplakia Using a MAGE-A-based Immunoscore
Oral squamous cell carcinomas (OSCC) is among the most common malignancies worldwide. Early detection and prevention of OSCC is thought to have the highest potential to reduce morbidity and mortality.
- Conditions
- Oral Leukoplakia, Oral Leukoplakia of Tongue, Oral Leukoplakia of Gingiva, Oral Lichen Planus
- Trial name
- PREDICT-OLP (NCT03975322)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Tongue Squamous Cell Carcinoma
Oncological Outcome of Contralateral Submental Artery Island Flap Versus Primary Closure in Tongue Squamous Cell Carcinoma
The purpose of this study is to compare the oncological and functional results of the contralateral submental flap with primary closure for reconstruction of tongue squamous cell carcinoma.
- Trial name
- NCT03440151
- Testing
- contralateral submental flap for tongue cancer defect, primary closure for tongue cancer defect
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Cairo University
Head and Neck Cancer
Quality-Of-Life Assessment in Patients With Head and Neck Cancer Treated With Radiation Therapy
RATIONALE: Gathering information over time about patients' quality-of-life and satisfaction with care may help doctors plan the best treatment and help patients live more comfortably.
- Trial name
- NCT01210872
- Testing
- questionnaire administration, quality-of-life assessment, standard follow-up care
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Georges Francois Leclerc
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland